Targeted Therapy for Malignancies in the Nervous System

Topic Information

Dear Colleagues,

Central nervous system (CNS) malignancies, a diverse group of neoplasms occurring in the brain, brainstem, spinal cord, or epen-dymal lining of the ventricles, are categorized as the most aggressive and deadly types of cancer. Glioblastoma is the most malignant CNS neoplasm, accounting for more than 60% of all brain tumor cases in adults. Over the past decade, the identification of molecular biomarkers in CNS tumors and the translation of these findings to patient care have been the focus of remarkable efforts globally. With the development of drug therapy, significant progress has been made in the basic research and clinical investigations of brain me-tastases and primary central nervous system lymphoma. However, outside of temozolomide (the first-line drug for glioblastoma treatment), bevacizumab is the only targeted therapy approved by the U.S. Food and Drug Administration (FDA) for glioblastoma. It is imperative we identify the targetable and actionable driver genomic alterations to expand the list of therapeutic options. Challenges in developing effective targeted molecular therapies include intratumoral heterogeneity, clonal selection, tumor evolution, and ineffective drug delivery due to the blood–brain barrier. This Special Issue aims to highlight the latest advances in targeted therapies in CNS malignancies and calls for original research articles, reviews, and case reports on the identification of druggable targets, targeted drug delivery approaches, novel combination therapies, and drug resistance. We hope the work presented will advance our understanding of the clinical management of CNS malignancies and pave the way toward novel therapeutic strategies for clinical application.

Dr. Tao Li
Dr. Bo Jiang
Dr. Huijie Wei
Dr. Shengping Yu
Topic Editors

Keywords

Participating Journals

Journal Name	Impact Factor	CiteScore	Launched Year	First Decision (median)	APC
BioMedInformatics biomedinformatics	-	3.4	2021	22.9 Days	CHF 1000
Cancers cancers	4.4	8.8	2009	20.3 Days	CHF 2900
Clinical and Translational Neuroscience ctn	1.1	-	2017	21.9 Days	CHF 1000
Current Oncology curroncol	3.4	4.9	1994	21.5 Days	CHF 2200
Journal of Clinical Medicine jcm	2.9	5.2	2012	17.7 Days	CHF 2600

Preprints.org is a multidisciplinary platform offering a preprint service designed to facilitate the early sharing of your research. It supports and empowers your research journey from the very beginning.

MDPI Topics is collaborating with Preprints.org and has established a direct connection between MDPI journals and the platform. Authors are encouraged to take advantage of this opportunity by posting their preprints at Preprints.org prior to publication:

1. Share your research immediately: disseminate your ideas prior to publication and establish priority for your work.
2. Safeguard your intellectual contribution: Protect your ideas with a time-stamped preprint that serves as proof of your research timeline.
3. Boost visibility and impact: Increase the reach and influence of your research by making it accessible to a global audience.
4. Gain early feedback: Receive valuable input and insights from peers before submitting to a journal.
5. Ensure broad indexing: Web of Science (Preprint Citation Index), Google Scholar, Crossref, SHARE, PrePubMed, Scilit and Europe PMC.

Published Papers (2 papers)

Order results

Content type Publication Date

Result details

Normal Extended Compact

Journals

All BioMedInformatics Cancers CTN Current Oncology JCM

Show export options expand_more Show export options expand_less

Select all

Export citation of selected articles as:

Plain Text BibTeX BibTeX (without abstracts) Endnote Endnote (without abstracts) Tab-delimited RIS

Error

Oops... you haven't selected anything for export.

Ok

clear

11 pages, 6423 KB  

Open AccessCase Report

Conversion in a Resectable Tumor after Denosumab Neoadjuvant in a Large Dorsal Giant Cells Tumor: A Case Report and a Literature Review

by María Sereno, Silvia Roa Franco, Laura de la Reina, José Luis Campo-Cañaveral de la Cruz, Marta Muñoz de Legaría and Enrique Casado Saénz

Curr. Oncol. 2023, 30(10), 9335-9345; https://doi.org/10.3390/curroncol30100675 - 21 Oct 2023

Cited by 1 | Viewed by 2251

Abstract

Giant cell tumors of bone are a rare entity, usually occurring in young patients and characteristically arising in the long bones. The spinal location is rare and usually presents with pain and/or neurological symptoms. The treatment of choice is surgery. Treatment with Denosumab, [...] Read more.

Giant cell tumors of bone are a rare entity, usually occurring in young patients and characteristically arising in the long bones. The spinal location is rare and usually presents with pain and/or neurological symptoms. The treatment of choice is surgery. Treatment with Denosumab, a bisphosphonate inhibitor of RANK-L, which is highly expressed in these tumors, has shown extensive activity in unresectable patients or those undergoing incomplete surgery. Preoperative treatment with this drug is gaining increasing interest, as its high potency in tumor reduction in this subtype of neoplasm has allowed resectability in selected patients. We present the case of a young patient with a large spinal tumor who, after neoadjuvant Denosumab, underwent complete en bloc surgery with clean margins and a great pathological response. Full article

(This article belongs to the Topic Targeted Therapy for Malignancies in the Nervous System)

►▼ Show Figures

Figure 1

17 pages, 9367 KB  

Open AccessArticle

Epithelial Membrane Protein-3 and Chitinase-3-like Protein-1 as New Prognostic Predictors of Glioma, a Two-Gene Study

by Kecheng Shen, Jiandong Zhu, Shijie Zhou, Xin Jin, Weiwei Zhai, Liang Sun, Jiang Wu and Zhengquan Yu

Curr. Oncol. 2023, 30(10), 8686-8702; https://doi.org/10.3390/curroncol30100629 - 23 Sep 2023

Cited by 2 | Viewed by 2275

Abstract

Background: Glioblastoma multiforme is the most common primary intracranial tumor, with a high degree of malignancy, poor therapeutic effect, and poor prognosis. According to previous studies, CHI3L1 and EMP3 are two independent tumor predictors that are of great significance for the prognostic prediction [...] Read more.

Background: Glioblastoma multiforme is the most common primary intracranial tumor, with a high degree of malignancy, poor therapeutic effect, and poor prognosis. According to previous studies, CHI3L1 and EMP3 are two independent tumor predictors that are of great significance for the prognostic prediction of other tumors, and their expression levels may be related to the prognosis of glioma patients. Methods: using Oncomine, Gene Expression Profiling Interactive Analysis (GEPIA), the Chinese Glioma Genome Atlas (CGGA), cBioPortal, LinkedOmics, and other databases, 693 glioma patients were screened to analyze the relationship between EMP3 and CHI3L1 expression and prognosis in glioma patients. Results: low-grade glioma patients with a low expression of EMP3/CHI3L1 had a better prognosis, and the combination of EMP3/CHI3L1 is a new predictor for glioma patients. Conclusion: We used the TCGA and CGGA databases to analyze the effect of EMP3 and CHI3L1 expression on the prognosis of glioma patients and their correlation with gene expression using bioinformation analysis. The results showed that low-grade glioma patients with a low expression of EMP3 and CHI3L1 had a better prognosis, and EMP3 and CHI3L1 co-expression genes were correlated. The combination of these two factors could be a new prognostic index for glioma patients. Full article

(This article belongs to the Topic Targeted Therapy for Malignancies in the Nervous System)

►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less

Select all

Export citation of selected articles as:

Plain Text BibTeX BibTeX (without abstracts) Endnote Endnote (without abstracts) Tab-delimited RIS

 

Error

Oops... you haven't selected anything for export.

Ok

clear

Displaying articles 1-2